On May 19, 2020 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga-resistant prostate cancer and leukemia, reported it has entered into a securities purchase agreement with its Board of Directors and its Chief Executive Officer pursuant to which it sold 594,615 shares of Common Stock for gross proceeds of $810,000 (Press release, Trovagene, MAY 19, 2020, View Source [SID1234558270]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cardiff Oncology intends to utilize the proceeds of this private placement to help advance its ongoing clinical development programs in KRAS-mutated metastatic colorectal cancer (mCRC), Zytiga-resistant metastatic castration-resistant prostate cancer (mCRPC) and relapsed or refractory acute myeloid leukemia (AML).

"We are grateful for the support that our Board is providing to us," said Dr. Mark Erlander, Chief Executive Officer of Cardiff Oncology. "Our focus is on advancing the clinical development of onvansertib in cancer indications representing the greatest medical need for new, safe and effective treatment options for patients."